683 related items for PubMed ID: 15915009
1. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
Dusser D, Vicaut E, Lefrançois G, Formoterol HFA group.
Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
[Abstract] [Full Text] [Related]
2. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
Bousquet J, Huchon G, Leclerc V, Vicaut E, Lefrançois G.
Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
[Abstract] [Full Text] [Related]
3. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
Bousquet J, Guenolé E, Duvauchelle T, Vicaut E, Lefrançois G.
Respiration; 2005; 72 Suppl 1():13-9. PubMed ID: 15915008
[Abstract] [Full Text] [Related]
4. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
Molimard M, Guenolé E, Duvauchelle T, Vicaut E, Lefrançois G.
Respiration; 2005; 72 Suppl 1():28-34. PubMed ID: 15915010
[Abstract] [Full Text] [Related]
5. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
Busse W, Levine B, Andriano K, Lavecchia C, Yegen U.
Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
[Abstract] [Full Text] [Related]
6. Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients.
Langley SJ, Houghton CM, Singh SD.
Respiration; 2005 Oct; 72 Suppl 1():35-7. PubMed ID: 15915011
[Abstract] [Full Text] [Related]
7. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
Houghton CM, Langley SJ, Singh SD, Holden J, Monici Preti AP, Acerbi D, Poli G, Woodcock A.
Br J Clin Pharmacol; 2004 Oct; 58(4):359-66. PubMed ID: 15373928
[Abstract] [Full Text] [Related]
8. Bronchodilation of formoterol administered with budesonide: device and formulation effects.
Miller CJ, Senn S, Mezzanotte WS.
Contemp Clin Trials; 2008 Mar; 29(2):114-24. PubMed ID: 17625985
[Abstract] [Full Text] [Related]
9. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial.
Noonan M, Rosenwasser LJ, Martin P, O'Brien CD, O'Dowd L.
Drugs; 2006 Mar; 66(17):2235-54. PubMed ID: 17137405
[Abstract] [Full Text] [Related]
10. Efficacy and tolerability of once-daily budesonide/formoterol pressurized metered-dose inhaler in adults and adolescents with asthma previously stable with twice-daily budesonide/ formoterol dosing.
Kerwin EM, Oppenheimer JJ, LaForce C, Parasuraman B, Miller CJ, O'Dowd L, Goldman M.
Ann Allergy Asthma Immunol; 2009 Jul; 103(1):62-72. PubMed ID: 19663129
[Abstract] [Full Text] [Related]
11. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.
Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, Silkoff PE.
Drugs; 2009 Jul; 69(5):549-65. PubMed ID: 19368417
[Abstract] [Full Text] [Related]
12. Comparable long-term safety and efficacy of a novel budesonide/formoterol pressurized metered-dose inhaler versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma.
Morice AH, Hochmuth L, Ekelund J, Thorén A, Puterman AS.
Pulm Pharmacol Ther; 2008 Jul; 21(1):32-9. PubMed ID: 17118686
[Abstract] [Full Text] [Related]
13. The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma.
Murphy K, Nelson H, Parasuraman B, Boggs R, Miller C, O'Dowd L.
Curr Med Res Opin; 2008 Mar; 24(3):879-94. PubMed ID: 18267051
[Abstract] [Full Text] [Related]
14. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA, Rooklin A, Schoaf L, Scott C, Ellsworth A, House K, Dorinsky P.
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[Abstract] [Full Text] [Related]
15. Lung function and asthma control with beclomethasone and formoterol in a single inhaler.
Huchon G, Magnussen H, Chuchalin A, Dymek L, Gonod FB, Bousquet J.
Respir Med; 2009 Jan; 103(1):41-9. PubMed ID: 18977646
[Abstract] [Full Text] [Related]
16. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
Berger WE, Noonan MJ.
J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
[Abstract] [Full Text] [Related]
17. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
FitzGerald JM, Boulet LP, Follows RM.
Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
[Abstract] [Full Text] [Related]
18. Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma.
Morice AH, Peterson S, Beckman O, Osmanliev D.
Int J Clin Pract; 2007 Nov; 61(11):1874-83. PubMed ID: 17887990
[Abstract] [Full Text] [Related]
19. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma.
Corren J, Korenblat PE, Miller CJ, O'Brien CD, Mezzanotte WS.
Clin Ther; 2007 May; 29(5):823-843. PubMed ID: 17697902
[Abstract] [Full Text] [Related]
20. Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPD.
Brusasco V, Canonica GW, Dal Negro R, Scano G, Paggiaro P, Fabbri LM, Barisione G, D'Amato G, Varoli G, Baroffio M, Milanese M, Mereu C, Crimi E.
J Aerosol Med Pulm Drug Deliv; 2011 Oct; 24(5):235-43. PubMed ID: 21689019
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
